Suppr超能文献

钙通道阻滞剂相关的外周性水肿:能否得到解决?

Calcium channel blocker-related periperal edema: can it be resolved?

作者信息

Sica Domenic A

机构信息

Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298-0160, USA.

出版信息

J Clin Hypertens (Greenwich). 2003 Jul-Aug;5(4):291-4, 297. doi: 10.1111/j.1524-6175.2003.02402.x.

Abstract

Calcium channel blocker (CCB)-related edema is quite common in clinical practice and can effectively deter a clinician from continued prescription of these drugs. Its etiology relates to a decrease in arteriolar resistance that goes unmatched in the venous circulation. This disproportionate change in resistance increases hydrostatic pressures in the precapillary circulation and permits fluid shifts into the interstitial compartment. CCB-related edema is more common in women and relates to upright posture, age, and the choice and dose of the CCB. Once present it can be slow to resolve without intervention. A number of strategies exist to treat CCB-related edema, including switching CCB classes, reducing the dosage, and/or adding a known venodilator such as a nitrate, an angiotensin-converting enzyme inhibitor, or an angiotensin-receptor blocker to the treatment regimen. Angiotensin-converting enzyme inhibitors have been best studied in this regard. Diuretics may alter the edema state somewhat, but at the expense of further reducing plasma volume. Traditional measures such as limiting the amount of time that a patient is upright and/or considering use of graduated compression stockings are useful adjunctive therapies. Discontinuing the CCB and switching to an alternative antihypertensive therapy will resolve the edema.

摘要

钙通道阻滞剂(CCB)相关的水肿在临床实践中相当常见,会有效阻碍临床医生继续开具这些药物。其病因与小动脉阻力降低有关,而静脉循环中未出现相应变化。这种阻力的不均衡变化会增加毛细血管前循环中的流体静压,使液体转移至间质腔隙。CCB相关的水肿在女性中更为常见,与直立姿势、年龄以及CCB的选择和剂量有关。一旦出现,若不干预,水肿消退可能较慢。有多种治疗CCB相关水肿的策略,包括更换CCB类别、减少剂量,和/或在治疗方案中添加已知的静脉扩张剂,如硝酸盐、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂。在这方面,血管紧张素转换酶抑制剂的研究最为充分。利尿剂可能会在一定程度上改变水肿状态,但代价是进一步降低血浆容量。传统措施,如限制患者直立时间和/或考虑使用分级压力弹力袜,是有用的辅助治疗方法。停用CCB并改用其他抗高血压疗法可消除水肿。

相似文献

1
Calcium channel blocker-related periperal edema: can it be resolved?
J Clin Hypertens (Greenwich). 2003 Jul-Aug;5(4):291-4, 297. doi: 10.1111/j.1524-6175.2003.02402.x.
3
Evaluation of a Common Prescribing Cascade of Calcium Channel Blockers and Diuretics in Older Adults With Hypertension.
JAMA Intern Med. 2020 May 1;180(5):643-651. doi: 10.1001/jamainternmed.2019.7087.
4
Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system.
J Hum Hypertens. 2009 Aug;23(8):503-11. doi: 10.1038/jhh.2008.157. Epub 2009 Jan 15.
5
Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
J Cardiovasc Nurs. 2009 Sep-Oct;24(5):380-9. doi: 10.1097/JCN.0b013e3181aed18e.
6
Managing peripheral edema in patients with arterial hypertension.
Am J Ther. 2009 Nov-Dec;16(6):543-53. doi: 10.1097/MJT.0b013e3181afbf9f.
7
Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance.
J Clin Hypertens (Greenwich). 2003 Sep-Oct;5(5):330-5. doi: 10.1111/j.1524-6175.2003.02216.x.
8
An evaluation of a potential calcium channel blocker-lower-extremity edema-loop diuretic prescribing cascade.
J Am Pharm Assoc (2003). 2018 Sep-Oct;58(5):534-539.e4. doi: 10.1016/j.japh.2018.06.014. Epub 2018 Jul 20.
10
Reduced Lymphatic Function Predisposes to Calcium Channel Blocker Edema: A Randomized Placebo-Controlled Clinical Trial.
Lymphat Res Biol. 2020 Apr;18(2):156-165. doi: 10.1089/lrb.2019.0028. Epub 2019 Aug 20.

引用本文的文献

3
Assessment of the Tolerance of Dobenox Forte in Patients with Chronic Venous Disease.
Life (Basel). 2024 Mar 25;14(4):437. doi: 10.3390/life14040437.
4
Etiology of Drug-Induced Edema: A Review of Dihydropyridine, Thiazolidinedione, and Other Medications Causing Edema.
Cureus. 2024 Feb 1;16(2):e53400. doi: 10.7759/cureus.53400. eCollection 2024 Feb.
5
Edema related to treatment with psychotropic drugs.
J Neural Transm (Vienna). 2024 Mar;131(3):253-266. doi: 10.1007/s00702-024-02738-6. Epub 2024 Feb 14.
7
Amlodipine in the current management of hypertension.
J Clin Hypertens (Greenwich). 2023 Sep;25(9):801-807. doi: 10.1111/jch.14709. Epub 2023 Aug 7.
9
Stasis Dermatitis: An Overview of Its Clinical Presentation, Pathogenesis, and Management.
Am J Clin Dermatol. 2023 Mar;24(2):275-286. doi: 10.1007/s40257-022-00753-5. Epub 2023 Feb 17.
10
Calcium-channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients.
Br J Clin Pharmacol. 2023 Feb;89(2):853-864. doi: 10.1111/bcp.15541. Epub 2022 Oct 6.

本文引用的文献

1
Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine.
J Hypertens. 2003 May;21(5):1003-10. doi: 10.1097/00004872-200305000-00026.
5
Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension.
Am J Hypertens. 2003 Jan;16(1):51-8. doi: 10.1016/s0895-7061(02)03153-9.
6
Peripheral edema.
Am J Med. 2002 Nov;113(7):580-6. doi: 10.1016/s0002-9343(02)01322-0.
7
10
Dihydropyridine calcium channel blockers and peripheral side effects.
J Hum Hypertens. 2001 Oct;15(10):745-6. doi: 10.1038/sj.jhh.1001248.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验